Read the source behind the term

Medicine and compounding reading

• How a pharmacy prepares a medicine

  U.S. Food and Drug Administration

• Claims made on care websites

  U.S. Food and Drug Administration

• Reading a product code without assuming approval

  U.S. Food and Drug Administration

The compounding questions page is the place to read how preparing a medicine differs from supplying a finished approved product. Keep the proposed product name beside you while reading.

As of November 3, 2026, compounded drugs lack FDA approval and are not reviewed by the agency before marketing for safety, quality or effectiveness.

A website may point to a product’s identifying number in a government directory, called its National Drug Code (NDC). FDA says the code and directory entry do not establish approval of the product, as of November 3, 2026. A listing also does not show that FDA checked the information it contains.

• Ask which part of a source supports the exact claim being made.
• Keep the full product name and form with any page you save.

The current draft policy

HHS means the Department of Health and Human Services. Its draft published October 30, 2026 describes how it plans to enforce compounding rules for certain peptide ingredients.

The draft concerns pharmacies and physicians licensed by a state who prepare medicine for an individual patient’s prescription. If every condition is met, HHS says it plans not to act against those pharmacies and physicians for using the covered peptide ingredients. This is an enforcement policy: a statement about when the department plans to act on a rule violation.

The covered peptide ingredients are KPV, TB-500, semax, MOTS-c, BPC-157 and epitalon. These are ingredient names, not names of illnesses or approved treatments. Appendix B specifies the exact ingredient versions and the ways they may be given under the policy.

The policy covers a single peptide ingredient in a preparation; blends are outside it. It also excludes 503B outsourcing facilities.

A 503B outsourcing facility is a place that chooses to register with FDA to prepare sterile medicines. Sterile describes medicines with no living germs in them. These places often make batches for hospitals or clinics and can work without prescriptions naming each recipient, as of November 3, 2026.

The 503A Bulks List names raw ingredients allowed through one part of the law for medicines prepared for individual prescriptions, as of November 3, 2026. Other parts of the ingredient test concern official drug-quality standards or an ingredient used in an FDA-approved medicine.

As of November 3, 2026, that list includes none of the six ingredients above, and the HHS draft gives no FDA approval. The draft is a separate policy about when HHS plans not to act, so the missing list entry alone does not describe that policy.

The draft does not change the law or create a legal right to compound. It sets out HHS’s enforcement plans; a pharmacy still needs to explain how the proposed preparation fits the policy conditions and the other rules.

In its October 30, 2026 publication, HHS gave an official account that the July 2026 committee favored six of the seven peptides: the six covered by the draft. The FDA page for that meeting still lacked minutes, a transcript or a record of each member’s vote as of November 3, 2026. The HHS account exists even though FDA has not posted that meeting record.

A committee recommendation is advice, not the final rule that changes the ingredient list.

• The draft policy notice

  U.S. Department of Health and Human Services / Government Publishing Office

• The policy text and its limits

  U.S. Department of Health and Human Services

Read the conditions rather than treating a headline about the policy as a decision about your care. Ask the pharmacy to show which Appendix B entry matches the exact ingredient and how you would take it. Ask whether the medicine would come from a pharmacy preparing your own prescription or a 503B facility, and which policy conditions apply.

License records and the conversation

• State board contact directory

  Federation of State Medical Boards

• Look up a pharmacy license

  U.S. Food and Drug Administration

• The boards’ guidance on prescribing

  Federation of State Medical Boards

Open the board directory, then choose the state or territory whose doctor records you need.

FDA’s pharmacy page leads to state pharmacy license searches.

Treat this federation’s text as guidance to boards, with enforceable rules supplied by each state, as of November 3, 2026.

Use a board record to match a name and role. Use the prescribing guidance to frame questions about how a conversation and assessment take place. Neither task is completed by seeing a badge on a website.

• Ask which licensing board applies to the person you will speak with.
• Ask where follow-up questions go after a decision.

Coverage reading

• Medicare’s information about weight-loss drugs

  Medicare.gov, Centers for Medicare & Medicaid Services

Use Medicare’s own coverage information when that is the plan you are asking about. Keep your question tied to the product and proposed use rather than to a broad promise about peptide care.

Ask the plan: “Does this answer cover the visit, the medicine or both? What else do you need to decide whether you will pay?” Then ask the service quoting the fee which parts of the bill that answer would cover. Keep the quote separate from the coverage response, so a missing answer stays visible.

Problems, urgent help and reports

• Severe allergic reactions

  U.S. National Library of Medicine, National Institutes of Health

• Report a medicine problem

  U.S. Food and Drug Administration

MedlinePlus describes severe allergic reactions and when emergency help is needed.

FDA’s MedWatch program collects reports about medical-product problems. People receiving care can send those reports themselves, alongside reports from health professionals.

Keep reporting separate from getting help with a current problem. A report is a record, not a response from the prescriber. Ask the care service how problems are handled between visits.

If the next step is still unclear, write the unanswered question on your list and ask the care service for the missing information. Keep the source with the question so the next person can see what prompted it.